Enalozid (enalapril, hydrochlorothiazide) tablets 12.5 mg. №30


Manufacturer: Ukraine

Treatment of hypertension in patients who are indicated for combination therapy.



Enalozid 12.5 mg. Storage
active substances: enalapril, hydrochlorothiazide;

1 tablet contains: enalapril maleate in terms of 100% of the substance – 10 mg, hydrochlorothiazide in terms of 100% of the substance – 12.5 mg;

Enalozid 12.5 mg. Excipients: lactose monohydrate, potato starch, povidone, calcium stearate.

Enalozid 12.5 mg. Dosage form

Basic physical and chemical properties: tablets of white or white with a cream shade of color, with a flat surface, a facet and a line or without a line.

Pharmacotherapeutic group
Combined drugs of ACE inhibitors. Enalapril and diuretics. ATX code C09B A02.

Pharmacological properties


The drug is a combination of an angiotensin-converting enzyme inhibitor (enalapril maleate) and a diuretic (hydrochlorothiazide).

Angiotensin converting enzyme (ACE) is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the pressor substance angiotensin II. After absorption, enalapril is hydrolyzed to enalaprilat, which inhibits ACE inhibitors. Inhibition of ACE leads to a decrease in plasma levels of angiotensin II, which leads to increased plasma renin activity (due to inhibition of negative feedback during renin release) and decreased aldosterone secretion.

ACE is identical to kininase II. Enalapril can also block the breakdown of bradykinin, which is a potent vasodepressant peptide. However, the role of this fact in the therapeutic effects of enalapril remains unknown. While the mechanism by which enalapril lowers blood pressure is primarily associated with inhibition of the activity of the renin-angiotensin-aldosterone system, which plays a major role in regulating blood pressure, enalapril may have an antihypertensive effect even in patients with low-renin hypertension.

Hydrochlorothiazide (HCT) is a diuretic and antihypertensive agent that increases plasma renin activity. The antihypertensive effects of the two components are additive and usually last for 24 hours. Although enalapril alone has an antihypertensive effect even in patients with low-renin hypertension, co-administration with hydrochlorothiazide in such patients results in a greater reduction in blood pressure. The enalapril component of the drug generally reduces the reduction in potassium caused by hydrochlorothiazide.

Treatment of hypertension in patients receiving combination therapy.

Hypersensitivity to enalapril and to other angiotensin-converting enzyme (ACE) inhibitors, hydrochlorothiazide and to other sulphonamide derivatives or to other components of the medicinal product.
History of angioneurotic edema associated with treatment with angiotensin-converting enzyme inhibitors.
Hereditary or idiopathic angioneurotic edema.
Severe renal impairment (creatinine clearance less than 30 ml / min or serum creatinine level exceeds 265 μmol / l (3 mg / 100 ml)).
Renal artery stenosis.
Contraindicated during hemodialysis.
Clinical condition after kidney transplantation.
Severe liver dysfunction.
Anuria, primary hyperaldosteronism.
Hypokalemia or hyperkalemia resistant to treatment.
Refractory hyponatremia.
Symptomatic hyperuricemia (gout).
Pregnant women or women planning to become pregnant (see “Use during pregnancy or breast-feeding”).
Enalapril should not be used with aliskiren-containing products in patients with diabetes mellitus or renal impairment (GFR <60 ml / min / 1.73 m2).